Inovio Pharmaceuticals (NASDAQ:INO) Receives Market Outperform Rating from JMP Securities

Inovio Pharmaceuticals (NASDAQ:INO)‘s stock had its “market outperform” rating restated by JMP Securities in a report issued on Friday,Benzinga reports. They currently have a $18.00 price objective on the biopharmaceutical company’s stock.

A number of other research analysts have also weighed in on the stock. Royal Bank of Canada reduced their price objective on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a research note on Friday, November 15th. Oppenheimer cut their price target on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a report on Monday, November 18th. Finally, HC Wainwright decreased their price objective on Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating on the stock in a research note on Monday, November 18th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $12.80.

Inovio Pharmaceuticals Stock Down 5.3 %

Shares of NASDAQ:INO opened at $1.98 on Friday. The company has a 50-day moving average price of $3.42 and a two-hundred day moving average price of $6.10. Inovio Pharmaceuticals has a twelve month low of $1.74 and a twelve month high of $14.75. The firm has a market capitalization of $51.68 million, a PE ratio of -0.95 and a beta of 0.84.

Hedge Funds Weigh In On Inovio Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in INO. Bank of New York Mellon Corp bought a new position in shares of Inovio Pharmaceuticals in the 2nd quarter worth $661,000. Rhumbline Advisers increased its stake in Inovio Pharmaceuticals by 5,943.0% in the second quarter. Rhumbline Advisers now owns 38,494 shares of the biopharmaceutical company’s stock valued at $311,000 after acquiring an additional 37,857 shares during the last quarter. American Century Companies Inc. increased its stake in Inovio Pharmaceuticals by 62.2% in the second quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock valued at $255,000 after acquiring an additional 12,100 shares during the last quarter. Cornercap Investment Counsel Inc. purchased a new stake in Inovio Pharmaceuticals during the second quarter valued at about $184,000. Finally, Dimensional Fund Advisors LP bought a new stake in Inovio Pharmaceuticals during the second quarter worth about $605,000. 26.79% of the stock is currently owned by institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.